A new study published in the journal Cell reveals a crucial interplay between DNA and RNA epigenetics, demonstrating that these mechanisms work together as a complementary system for precise gene regulation. This discovery has significant implications for understanding cell function, development, and potentially revolutionizing cancer therapies.
Genes provide the instructions for bodily function, but their expression requires careful regulation. Epigenetics, encompassing mechanisms like DNA and RNA modifications, acts as "markers" on genes, controlling their activity without altering the underlying DNA or RNA sequence.
Previously, DNA and RNA epigenetics were studied as separate, independent systems. However, researchers led by François Fuks from the Laboratory of Cancer Epigenetics, ULB Faculty of Medicine, ULB-Cancer Research Center, and Jules Bordet Institute, H.U.B., have now discovered a crucial connection. Their research shows that these two epigenetic mechanisms form a complementary system. DNA epigenetics appears to organize the available genes, while RNA epigenetics dynamically adjusts their use.
How it is work:
The study demonstrates that the combined presence of DNA and RNA epigenetic markers on a gene enables more effective gene activation. Conversely, if one of these processes is disrupted, the gene's activity decreases. This mechanism is particularly important during key cellular processes like development and specialization, as observed in embryonic stem cells. This combined regulation allows for incredibly precise control of gene activity, essential for organism development and cell function.
Potential:
This breakthrough, published on January 17th in Cell, unveils a new mode of gene control with far-reaching implications. It enhances our understanding of cellular processes and how disruptions in these mechanisms can contribute to diseases like cancer.
Critically, this discovery opens new avenues for cancer treatment. The complementary regulation system offers the potential to develop therapies based on "epigenetic drugs" that simultaneously target both DNA and RNA. Researchers hope this approach will lead to more precise and personalized cancer treatments, capable of restoring balance to diseased cells.
Prof. Fuks' team is currently conducting further research to explore the clinical applications of these findings and investigate the potential of epigenetic therapies targeting both DNA and RNA.
0 Comments